Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
FRI633 Financial Benefits Of Renal Dose-adjusted Dipeptidyl Peptidase-4 Inhibitors For Patients With Type 2 Diabetes And Chronic Kidney Disease: A Multicenter Study Utilizing Common Data Model
View through CrossRef
Abstract
Disclosure: H. Choe: None. Y. Ko: None. S. Moon: None. C.H. Ahn: None. K. Ha: None. H. Lee: None. J. Bae: None. H. Joo: None. H. Lee: None. J. Sohn: None. D. Kim: None. S. Kim: None. K. Kim: None. Y. Cho: None.
Objective: To estimate the economic benefit of replacing non-renal dose adjusted (NRDA) dipeptidyl peptidase-4 (DPP4) inhibitors with renal dose adjusted (RDA) DPP4 inhibitors in patients with impaired kidney function and type 2 diabetes. Patients and Methods: This multicenter study analyzed a total of 67,964,996 prescription records of five teaching hospitals in Korea from January 1, 2012 to December 31, 2018 using a common data model. Prescription patterns of NRDA and RDA DPP4 inhibitors were subgrouped based on estimated glomerular filtration rate (eGFR) determined by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Results: NRDA DPP4 inhibitors were more frequently prescribed to patients with impaired kidney function than those with preserved kidney function (25.7%, 51.3%, 64.3%, and 71.6% in patients with eGFR of ≥60, <60, <45, and <30 mL/min/1.73m2, respectively). When applying the prescription pattern of DPP4 inhibitors for patients with preserved kidney function to those with impaired kidney function, cost savings per year were 7.6% for eGFR <60 mL/min/1.73m2 and 30.4% for eGFR <30 mL/min/1.73m2. Assuming patients with impaired kidney function are solely prescribed with RDA DPP4 inhibitors with appropriate dose reduction, 15.4% to 51.2% per year could be saved depending on kidney impairment severity. Conclusion: NRDA DPP4 inhibitors are frequently prescribed in patients with type 2 diabetes and CKD. Prescribing RDA DPP4 inhibitors with doses adjusted to individual kidney function could alleviate the economic burden associated with medical expenditure.
Presentation: Friday, June 16, 2023
Title: FRI633 Financial Benefits Of Renal Dose-adjusted Dipeptidyl Peptidase-4 Inhibitors For Patients With Type 2 Diabetes And Chronic Kidney Disease: A Multicenter Study Utilizing Common Data Model
Description:
Abstract
Disclosure: H.
Choe: None.
Y.
Ko: None.
S.
Moon: None.
C.
H.
Ahn: None.
K.
Ha: None.
H.
Lee: None.
J.
Bae: None.
H.
Joo: None.
H.
Lee: None.
J.
Sohn: None.
D.
Kim: None.
S.
Kim: None.
K.
Kim: None.
Y.
Cho: None.
Objective: To estimate the economic benefit of replacing non-renal dose adjusted (NRDA) dipeptidyl peptidase-4 (DPP4) inhibitors with renal dose adjusted (RDA) DPP4 inhibitors in patients with impaired kidney function and type 2 diabetes.
Patients and Methods: This multicenter study analyzed a total of 67,964,996 prescription records of five teaching hospitals in Korea from January 1, 2012 to December 31, 2018 using a common data model.
Prescription patterns of NRDA and RDA DPP4 inhibitors were subgrouped based on estimated glomerular filtration rate (eGFR) determined by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
Results: NRDA DPP4 inhibitors were more frequently prescribed to patients with impaired kidney function than those with preserved kidney function (25.
7%, 51.
3%, 64.
3%, and 71.
6% in patients with eGFR of ≥60, <60, <45, and <30 mL/min/1.
73m2, respectively).
When applying the prescription pattern of DPP4 inhibitors for patients with preserved kidney function to those with impaired kidney function, cost savings per year were 7.
6% for eGFR <60 mL/min/1.
73m2 and 30.
4% for eGFR <30 mL/min/1.
73m2.
Assuming patients with impaired kidney function are solely prescribed with RDA DPP4 inhibitors with appropriate dose reduction, 15.
4% to 51.
2% per year could be saved depending on kidney impairment severity.
Conclusion: NRDA DPP4 inhibitors are frequently prescribed in patients with type 2 diabetes and CKD.
Prescribing RDA DPP4 inhibitors with doses adjusted to individual kidney function could alleviate the economic burden associated with medical expenditure.
Presentation: Friday, June 16, 2023.
Related Results
Renal Ewing Sarcoma: A Case Report and Literature Review
Renal Ewing Sarcoma: A Case Report and Literature Review
Abstract
Introduction
Primary renal Ewing sarcoma is an extremely rare and aggressive tumor, representing less than 1% of all renal tumors. This case report contributes valuable in...
Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
AbstractObjectiveSulfonylureas and dipeptidyl peptidase‐4 inhibitors have a multidirectional effect on pancreatic cells. We aimed to evaluate the effects of these drugs on β‐ and α...
Therapeutic potential of SGLT-2 inhibitors and DDP4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia
Therapeutic potential of SGLT-2 inhibitors and DDP4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia
Background. Benign prostatic hyperplasia (BPH) has recently been linked to diabetes mellitus and insulin resistance. This study aims to explore whether the use of either sodium-glu...
Impact of Chronic Kidney Disease Stage on Lower-extremity Arthroplasty
Impact of Chronic Kidney Disease Stage on Lower-extremity Arthroplasty
End-stage renal disease and dialysis is commonly associated with poor outcomes after joint replacement surgery. The goal of this study was to evaluate postoperative complications i...
Renal Phenotype in Mitochondrial Diseases: A Multicenter Study
Renal Phenotype in Mitochondrial Diseases: A Multicenter Study
<b><i>Aims:</i></b> This study aimed to investigate associations between renal and extrarenal manifestations of mitochondrial diseases and their natural his...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Renal biopsy in diabetic patients: Histopathological and clinical correlations
Renal biopsy in diabetic patients: Histopathological and clinical correlations
Introduction: Diabetes is the leading cause of chronic kidney disease and end-stage kidney disease worldwide. A kidney biopsy in a diabetic patient must be considered when non-diab...
A Multi-Polygenic Risk Score Approach Incorporating Physical Activity Genotypes for Predicting Type 2 Diabetes and Associated Comorbidities: A FinnGen Study
A Multi-Polygenic Risk Score Approach Incorporating Physical Activity Genotypes for Predicting Type 2 Diabetes and Associated Comorbidities: A FinnGen Study
ABSTRACT
Aims/hypothesis
Genetic prediction of type 2 diabetes risk has proven difficult using current methods. Recent studies have shown...